Can a transplant drug slow rare muscle disease?
NCT ID NCT02481453
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tested the drug rapamycin in 44 adults with Inclusion Body Myositis, a rare muscle disease that causes progressive weakness. The goal was to see if rapamycin could stabilize muscle strength and improve immune function. Participants received either rapamycin or a placebo, and researchers measured changes in leg and hand strength over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCLUSION BODY MYOSITIS (IBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC Paris Est _Hôpital Pitié Salpêtrière
Paris, 75651, France
Conditions
Explore the condition pages connected to this study.